Drug delivery systems for vitreoretinal diseases
- 1 May 2004
- journal article
- review article
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 23 (3) , 253-281
- https://doi.org/10.1016/j.preteyeres.2004.02.003
Abstract
No abstract availableKeywords
This publication has 145 references indexed in Scilit:
- Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathyEye, 2002
- Photodynamic therapy with verteporfin for age-related macular degeneration11Prepared by the Ophthalmic Technology Assessment Committee Retina Panel, Donald S. Fong, MD, MPH, Chair, and approved by the American Academy of Ophthalmology’s Board of Trustees September 17, 2000.Ophthalmology, 2000
- Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to ratsPharmacological Research, 2000
- Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ countsOphthalmology, 1998
- Treatment of Cytomegalovirus Retinitis with a Sustained-Release Ganciclovir ImplantNew England Journal of Medicine, 1997
- The art of 'HAART': researchers probe the potential and limits of aggressive HIV treatmentsJAMA, 1997
- TNP-470 (AGM-1470): Mechanisms of action and early clinical developmentEuropean Journal Of Cancer, 1996
- Treatment of rheumatoid arthritis with monoclonal CD4 antibody M‐T151. Clinical results and immunopharmacologic effects in an open study, including repeated administrationArthritis & Rheumatism, 1991
- Lactic Acid Oligomer Microspheres Containing Hydrophilic DrugsJournal of Pharmaceutical Sciences, 1990
- Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine DeaminaseNew England Journal of Medicine, 1987